Search research articles
Contact Us
Filters
Showing results (21-30 of 54) with videos related to
Page
of 6
Sort By:
Stem Cell Reports
|
May 28, 2019
Nestin<sup>+</sup>NG2<sup>+</sup> Cells Form a Reserve Stem Cell Population in the Mouse Prostate
Maher Hanoun, Anna Arnal-Estapé, Maria Maryanovich, et al.
Blood Advances
|
October 27, 2020
Acute myeloid leukemia-induced remodeling of the human bone marrow niche predicts clinical outcome
Yiyang Chen, Lina Marie Hoffmeister, Yasmin Zaun, et al.
NPJ Digital Medicine
|
March 21, 2024
Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence
Jan-Niklas Eckardt, Waldemar Hahn, Christoph Röllig, et al.
British Journal of Haematology
|
April 9, 2024
Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study
Christoph Röllig, Christoph Schliemann, Leo Ruhnke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2023
Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL
Matthias Stelljes, Simon Raffel, Nael Alakel, et al.
Haematologica
|
February 13, 2023
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia
Nicola Gökbuget, Kristina Ihrig, Michael Stadler, et al.
Hemasphere
|
May 8, 2025
Age-stratified machine learning identifies divergent prognostic significance of molecular alterations in AML
Jan-Niklas Eckardt, Waldemar Hahn, Rhonda E Ries, et al.
Blood Advances
|
February 24, 2025
Gastrointestinal toxicity of Gemtuzumab Ozogamicin: Real-life data from the AMLCG, SAL and CELL study groups
Ricarda Knabe, Philippe Muller, Christoph Schliemann, et al.
Journal of Cancer Research and Clinical Oncology
|
September 28, 2022
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Maher Hanoun, Leo Ruhnke, Michael Kramer, et al.
Communications Medicine
|
May 17, 2023
Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
Jan-Niklas Eckardt, Christoph Röllig, Klaus Metzeler, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 54) with videos related to
Sort By:
Page
of 6
Stem Cell Reports
|
May 28, 2019
Nestin<sup>+</sup>NG2<sup>+</sup> Cells Form a Reserve Stem Cell Population in the Mouse Prostate
Maher Hanoun, Anna Arnal-Estapé, Maria Maryanovich, et al.
Blood Advances
|
October 27, 2020
Acute myeloid leukemia-induced remodeling of the human bone marrow niche predicts clinical outcome
Yiyang Chen, Lina Marie Hoffmeister, Yasmin Zaun, et al.
NPJ Digital Medicine
|
March 21, 2024
Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence
Jan-Niklas Eckardt, Waldemar Hahn, Christoph Röllig, et al.
British Journal of Haematology
|
April 9, 2024
Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study
Christoph Röllig, Christoph Schliemann, Leo Ruhnke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2023
Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL
Matthias Stelljes, Simon Raffel, Nael Alakel, et al.
Haematologica
|
February 13, 2023
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia
Nicola Gökbuget, Kristina Ihrig, Michael Stadler, et al.
Hemasphere
|
May 8, 2025
Age-stratified machine learning identifies divergent prognostic significance of molecular alterations in AML
Jan-Niklas Eckardt, Waldemar Hahn, Rhonda E Ries, et al.
Blood Advances
|
February 24, 2025
Gastrointestinal toxicity of Gemtuzumab Ozogamicin: Real-life data from the AMLCG, SAL and CELL study groups
Ricarda Knabe, Philippe Muller, Christoph Schliemann, et al.
Journal of Cancer Research and Clinical Oncology
|
September 28, 2022
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Maher Hanoun, Leo Ruhnke, Michael Kramer, et al.
Communications Medicine
|
May 17, 2023
Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
Jan-Niklas Eckardt, Christoph Röllig, Klaus Metzeler, et al.
Page
of 6